ER-positive early-stage breast cancer: Tamoxifen remains a reasonable option for women age greater than or equal to 70 years


The aim of the study was  to determine whether there is a benefit to adjuvant radiation therapy after breast-conserving surgery and tamoxifen in women age greater than or equal to 70 years with early-stage breast cancer.

In the period 1994-1999, 636 women ( age greater than or equal to 70 years ) who had clinical stage I ( T1N0M0 according to TNM classification ) estrogen receptor ( ER ) -positive breast carcinoma treated by lumpectomy were randomly assigned to receive Tamoxifen plus radiation therapy ( 317 women ) or Tamoxifen alone ( 319 women ).

Primary end points were time to local or regional recurrence, frequency of mastectomy, breast cancer-specific survival, time to distant metastasis, and overall survival.

Median follow-up for treated patients is now 12.6 years.

At 10 years, 98% of patients receiving Tamoxifen plus radiation therapy compared with 90% of those receiving Tamoxifen alone were free from local and regional recurrences.

There were no significant differences in time to mastectomy, time to distant metastasis, breast cancer-specific survival, or overall survival between the two groups.
Ten-year overall survival was 67% and 66% in the Tamoxifen plus radiation therapy and Tamoxifen alone groups, respectively.

In conclusion, with long-term follow-up, the previously observed small improvement in locoregional recurrence with the addition of radiation therapy remains.
However, this does not translate into an advantage in overall survival, distant disease-free survival, or breast preservation. Depending on the value placed on local recurrence, Tamoxifen alone remains a reasonable option for women age greater than or equal to 70 years with ER-positive early-stage breast cancer. ( Xagena )

Hughes KS et al, J Clin Oncol 2013; 31: 2382-2387

XagenaMedicine_2013



Indietro

Altri articoli

As part of an ongoing phase Ib/II study ( NCT02501096 ) in patients with selected solid tumors, Lenvatinib [ Lenvima...


Hepatocellular carcinoma ( HCC ) is responsible for over 600,000 deaths annually. In addition, hepatocellular carcinoma is characterized by its...


The Food and Drug Administration ( FDA ) has approved Keytruda ( Pembrolizumab ), the anti-PD-1 ( programmed death receptor-1...


The European Medicines Agency's ( EMA ) Committee for Medicinal Products for Human Use ( CHMP ) has adopted a...


The aim of American Society of Clinical Oncology ( ASCO ) Clinical Practice Guideline is to provide evidence-based recommendations to...


LABC ( Locally advanced breast cancer ) occurs at first presentation in about one-fifth of breast cancer patients worldwide, with...


HPV initiated ( HPV+ ) squamous cell carcinoma of oropharynx ( SCCOP ) has a unique epidemiology, biology, and genetic...


Glioblastoma ( GBM ) is the most common primary malignant adult brain tumor and, despite treatment advances in recent years,...


Although anti–CTLA-4 and anti–PD-1 monoclonal antibodies ( mAbs ) may overcome T-cell suppression, T-cell activation depends on the engagement of...


Researchers has assessed effectiveness, safety, and tolerability of Paclitaxel or Fluorouracil when added to radiation plus Cisplatin followed by adjuvant...